Marketed under the company’s DS Laboratories brand name, the product marks a new departure for the business, which has traditionally focused on topical skin care and hair care products.
But besides the fact that it is an oral product that will be marketed as a nutraceutical, the company is also claiming that clinical trials have proved it to be more effective, when compared to similar products on the market.
'A real breakthrough in nutraceutical research'
"We've developed our own proprietary tablet, which contains a unique composition of ingredients, to achieve a real breakthrough in neutraceutical research," said DS Healthcare President and CEO Daniel Khesin.
"Similar oral supplements already enjoy significant revenue in overseas markets where we have strong distribution. But none of the products we tested provided any real benefit to consumers. We have set out to improve this category, and we are very pleased with the outcome. Retailers worldwide have expressed great interest in our new tablet based on existing demand for competitors' products."
The company says that the product will be marketed as a treatment to help combat thinning hair, as well as improving and facilitating healthy hair growth, to ultimately ‘promote longer, stronger, thicker hair’.
Complex peptides and antioxidants
Although the full details of the formulation are not being disclosed, the company says that its development team has focused on a combination of complex peptides and antioxidants that serve to enhance the efficacy and potency of the product.
Initially the line will be launched in Mexico, during the first quarter of 2014, before being expanded into other major markets worldwide.
Currently the company markets a range of topical therapies and personal care products in 15 countries worldwide, but it is hoping that with the success of it DS Healthcare hair-thinning tablet, it will be able to expand that footprint.
Multinationals increasingly focused on hair-loss category
Over the past year there have been a number of significant developments in topical and oral treatments for thinning hair that have involved some of the biggest multinational players, including L’Oreal and Shiseido.
Back in June, Shiseido announced that it had teamed up with a Canadian bio-venture company and begun research on a regenerative treatment.
This newly set up framework agreement on a collaboration and technology transfer contract between Shiseido and RepliCel Life Sciences, is not gender specific in its research and will initially target the entire Asian region regarding the introduction of their "hair regenerative medicine technology (RCH-01)".
Shiseido will combine RepliCel's hair regenerative medicine technology and its own technology and aim to commercialize safe and effective hair regenerative medicine that integrates beauty and medicine to help those concerned about pattern baldness and thinning hair.
The Tokyo-based company has worked on hair research since it was formed in 1872, producing a number of tonics and oils, using its origin in pharmacology as an advantage. It has also been promoting scalp and hair biology research from genetic and cellular levels.